MOTS-c Adolescent (12 to 17) Dosing: What the Evidence Actually Shows

Why There Is No Established MOTS-c Dose for Adolescents

The short answer is that nobody has studied one. MOTS-c (mitochondrial open reading frame of the 12S rRNA type-c) was first characterized in 2015 when Lee and colleagues demonstrated that the peptide improved insulin sensitivity and prevented diet-induced obesity in mice [1]. That foundational paper used intraperitoneal injections of 5 mg/kg in C57BL/6 mice over a 7-day protocol. No human equivalent dose was derived in the study.

Since 2015, the published literature on exogenous MOTS-c administration remains confined to animal models and small-sample adult pilot protocols that have not undergone peer-reviewed publication of Phase II or III data [1][2]. The Endocrine Society's 2017 guideline on pediatric obesity does not mention MOTS-c. The AAP Clinical Practice Guideline for obesity in children and adolescents (2023) similarly excludes MOTS-c from its pharmacotherapy recommendations, listing only FDA-approved agents such as semaglutide (approved for ages 12 and older), liraglutide, and orlistat.

A search of ClinicalTrials.gov returns no registered interventional studies of exogenous MOTS-c in participants <18 years old [3]. Without Phase I pharmacokinetic and safety data in a pediatric population, any dose figure circulated online for adolescents is speculative.

Understanding MOTS-c as a Mitochondrial-Derived Peptide

MOTS-c belongs to a class of signaling molecules called mitochondrial-derived peptides (MDPs). These short peptides are encoded within the mitochondrial genome rather than nuclear DNA. The 16-amino-acid sequence of MOTS-c originates from the 12S rRNA gene region [1].

Endogenous MOTS-c circulates in human plasma. Levels appear to decline with age, and some observational studies have reported lower circulating concentrations in individuals with type 2 diabetes and obesity [2]. A 2019 cross-sectional analysis published in the Journal of Clinical Endocrinology & Metabolism found that plasma MOTS-c concentrations were inversely correlated with BMI and HOMA-IR in a cohort of 142 adults [4]. No equivalent measurement study has been conducted in adolescents.

The peptide activates the AMPK signaling pathway, which plays a central role in cellular energy homeostasis [1]. AMPK activation increases glucose uptake in skeletal muscle, reduces hepatic gluconeogenesis, and promotes fatty acid oxidation. These are the same downstream pathways targeted by metformin, a drug with decades of pediatric safety data [5].

The distinction matters. Metformin's pediatric profile was established through controlled trials spanning years. MOTS-c has none.

What Adult Research Protocols Use (and Why They Do Not Apply to Teens)

Compounding pharmacies and longevity clinics have used MOTS-c in adults at doses ranging from 5 mg to 10 mg administered subcutaneously three times per week. These protocols are not standardized, not FDA-reviewed, and not supported by published Phase II/III trial results. They derive loosely from allometric scaling of the murine doses reported by Lee et al., adjusted by body surface area conversion factors [1][6].

Allometric scaling from mice to adult humans typically uses a body surface area ratio of approximately 12.3 [6]. A murine dose of 5 mg/kg would, by this method, convert to roughly 0.4 mg/kg in a 60 kg adult. Scaling further down to an adolescent introduces compounding uncertainty. Adolescents between 12 and 17 span a body-mass range from approximately 35 kg to 80 kg or more. Puberty alters hepatic enzyme activity, renal clearance rates, and body composition in ways that make simple weight-based extrapolation unreliable [7].

The FDA's 2014 guidance on pediatric study design emphasizes that adolescents are not small adults. Differences in CYP450 enzyme maturation, glomerular filtration rate relative to body surface area, and the hormonal milieu of puberty can alter a drug's absorption, distribution, metabolism, and excretion profile in ways that adult PK data cannot predict [7].

Dr. Robert Lustig, a pediatric endocrinologist at UCSF, has stated regarding novel metabolic agents in youth: "The developing endocrine axis during puberty creates a pharmacokinetic environment that no adult trial can approximate. Dose-finding must be done separately in this population" [8].

Safety Considerations Specific to Adolescents

Prescribing an unvalidated peptide to a minor raises specific clinical and ethical concerns that go beyond simple dose uncertainty.

Growth and development. Adolescents aged 12 to 17 are actively growing. AMPK activation influences the mTOR pathway, which regulates cellular growth and proliferation [9]. The theoretical concern is that chronic AMPK stimulation could interfere with linear growth, though this has not been tested. In murine models, Lee et al. did not assess long-term skeletal growth outcomes [1].

Hormonal interactions. Puberty involves dramatic fluctuations in gonadotropins, sex steroids, growth hormone, and IGF-1. MOTS-c's insulin-sensitizing effects could theoretically interact with the physiologic insulin resistance of puberty, a normal adaptive process that supports growth. The Endocrine Society's clinical practice guideline on pediatric obesity notes that pharmacotherapy in this age group requires careful monitoring of growth velocity, bone age, and pubertal staging [10].

Mental health screening. The AAP 2023 guideline on pediatric obesity recommends mental health screening before initiating any weight-management pharmacotherapy in adolescents [11]. This applies regardless of the specific agent. Adolescents pursuing peptide therapies outside supervised clinical settings may bypass this step entirely, missing diagnoses of disordered eating, depression, or body dysmorphia.

Contamination risk. MOTS-c is not manufactured under FDA-inspected cGMP conditions for therapeutic use. Research-grade peptides obtained from compounding sources vary in purity. A 2023 analysis published in JAMA Network Open found that 39% of tested peptide products from online vendors contained inaccurate concentrations or undisclosed contaminants [12]. Exposing a developing adolescent to an impure or mislabeled product adds a layer of risk that does not exist with FDA-approved medications.

How MOTS-c Compares to FDA-Approved Options for Adolescent Metabolic Health

The comparison is stark. Several FDA-approved agents exist for adolescent obesity and metabolic dysfunction, each backed by randomized controlled trial data in the target age group.

Semaglutide 2.4 mg (Wegovy) received FDA approval for adolescents aged 12 and older in December 2022, based on the STEP TEENS trial (N=201). In that study, semaglutide produced a 16.1% reduction in BMI versus a 0.6% increase with placebo over 68 weeks [13]. The safety profile included gastrointestinal adverse events consistent with the adult experience.

Liraglutide 3.0 mg (Saxenda) was approved for adolescents aged 12 and older in 2020 based on a randomized trial (N=251) showing a 2.65% reduction in BMI standard deviation score versus placebo at 56 weeks [14].

Metformin, while not FDA-approved specifically for pediatric obesity, carries FDA approval for type 2 diabetes in children aged 10 and older and has extensive safety data spanning more than two decades of pediatric use [5].

MOTS-c has zero completed human trials in any age group. No efficacy endpoint has been measured. No adverse event profile has been characterized. No regulatory body has reviewed a new drug application. The gap between MOTS-c and approved alternatives is not a matter of degree. It is categorical.

What a Responsible Clinical Framework Would Require

If a research team were to study MOTS-c in adolescents, established regulatory and ethical standards would require several steps before a single dose could be administered.

First, adult Phase I and Phase II data establishing a preliminary safety and dose-response profile. The FDA Pediatric Research Equity Act (PREA) generally requires that pediatric studies be conducted only after sufficient adult data exist to inform the pediatric development plan [15].

Second, a pediatric study plan (PSP) submitted to and agreed upon by the FDA, including age-appropriate formulations, PK modeling using physiologically based pharmacokinetic (PBPK) approaches, and defined safety monitoring endpoints including growth velocity, bone density, pubertal progression, and hepatic and renal function panels.

Third, IRB approval with specific attention to the assent/consent process for minors. Adolescents aged 12 to 17 must provide assent, and a parent or legal guardian must provide informed consent. The FDA's guidance on pediatric clinical pharmacology studies outlines these requirements [7].

Fourth, a Data Safety Monitoring Board (DSMB) with pediatric expertise to review interim safety data at prespecified intervals.

None of these steps have been initiated for MOTS-c.

Endogenous MOTS-c Levels in Youth: What We Know

The limited data on endogenous MOTS-c concentrations come from adult cohorts. In the 2019 cross-sectional study by Du et al., mean plasma MOTS-c was approximately 300 pg/mL in metabolically healthy adults [4]. Values were significantly lower in subjects with type 2 diabetes (mean approximately 180 pg/mL, P<0.01).

No published study has measured endogenous MOTS-c levels in adolescents. It remains unknown whether circulating concentrations differ during puberty, whether levels correlate with insulin resistance in teens the way they appear to in adults, or whether a "deficiency" state can even be defined in this age group.

Without baseline physiologic data in the target population, the rationale for exogenous supplementation in adolescents lacks a pharmacologic foundation. You cannot correct a deficit that has not been measured.

The Bottom Line for Clinicians and Parents

MOTS-c is a biologically interesting mitochondrial-derived peptide with plausible mechanisms of metabolic benefit. Its preclinical profile in murine models is encouraging [1]. That is the entirety of the evidence base as of May 2026.

No dose of MOTS-c can be recommended for adolescents because no dose has been studied in adolescents, and no dose has been validated even in adults through a completed, peer-reviewed randomized controlled trial. Any provider offering MOTS-c to a patient under 18 outside of an IRB-approved research protocol is operating without a safety net.

For adolescents with obesity or metabolic dysfunction, the evidence supports structured behavioral interventions as first-line therapy, with FDA-approved pharmacotherapy (semaglutide, liraglutide, metformin, or phentermine/topiramate in older teens) as adjuncts when clinically indicated [11][13][14]. These agents have defined pediatric dose ranges, characterized adverse event profiles, and regulatory oversight.

MOTS-c may eventually earn a place in the metabolic pharmacopeia. For now, it belongs in the laboratory, not in a teenager's medicine cabinet.